Teratogenic potential of third-generation antiepileptic drugs: Current status and research needs
Tóm tắt
Từ khóa
Tài liệu tham khảo
Duncan, 2004
Borthen, 2009, Complications during pregnancy in women with epilepsy: population‐based cohort study, BJOG: Int J Obstet Gynaecol, 116, 1736, 10.1111/j.1471-0528.2009.02354.x
Borthen, 2015, Obstetrical complications in women with epilepsy, Seizure, 28, 32, 10.1016/j.seizure.2015.02.018
Brosh, 2011, Teratogenic determinants of first-trimester exposure to antiepileptic medications, J Popul Ther Clin Pharmacol, 18, e89
Grimaccia, 2015, Treating epilepsy during pregnancy: a systematic literature review of the impact of drug treatment on mother and foetus
Mølgaard-Nielsen, 2011, Newer-generation antiepileptic drugs and the risk of major birth defects, JAMA, 305, 1996, 10.1001/jama.2011.624
Wen, 2015, Antiepileptic drug use by pregnant women enrolled in Florida medicaid, Neurology, 84, 944, 10.1212/WNL.0000000000001304
Meador, 2008, Pregnancy registries in epilepsy a consensus statement on health outcomes, Neurology, 71, 1109, 10.1212/01.wnl.0000316199.92256.af
Pack, 2006, Therapy insight: clinical management of pregnant women with epilepsy, Nat Rev Neurol, 2, 190, 10.1038/ncpneuro0153
Canger, 1999, Malformations in offspring of women with epilepsy: a prospective study, Epilepsia, 40, 1231, 10.1111/j.1528-1157.1999.tb00851.x
Kaneko, 1999, Congenital malformations due to antiepileptic drugs, Epilepsy Res, 33, 145, 10.1016/S0920-1211(98)00084-9
Samrén, 1999, Antiepileptic drug regimens and major congenital abnormalities in the offspring, Ann Neurol, 46, 739, 10.1002/1531-8249(199911)46:5<739::AID-ANA9>3.0.CO;2-2
Kaaja, 2003, Major malformations in offspring of women with epilepsy, Neurology, 60, 575, 10.1212/01.WNL.0000044157.28073.DC
Vajda, 2004, Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy, J Clin Neurosci, 11, 854, 10.1016/j.jocn.2004.05.003
Holmes, 2004, The AED (antiepileptic drug) pregnancy registry: a 6-year experience, Arch Neurol, 61, 673, 10.1001/archneur.61.5.673
Wide, 2004, Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation‐wide, population‐based register study, Acta Paediatr, 93, 174, 10.1111/j.1651-2227.2004.tb00701.x
Cunnington, 2005, International lamotrigine pregnancy registry scientific advisory committee. Lamotrigine and the risk of malformations in pregnancy, Neurology, 64, 955, 10.1212/01.WNL.0000154515.94346.89
Wyszynski, 2005, Increased rate of major malformations in offspring exposed to valproate during pregnancy, Neurology, 64, 961, 10.1212/01.WNL.0000154516.43630.C5
Artama, 2005, Antiepileptic drug use of women with epilepsy and congenital malformations in offspring, Neurology, 64, 1874, 10.1212/01.WNL.0000163771.96962.1F
Perucca, 2005, Birth defects after prenatal exposure to antiepileptic drugs, Lancet Neurol, 4, 781, 10.1016/S1474-4422(05)70224-6
Morrow, 2006, Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK epilepsy and pregnancy register, J Neurol Neurosurg Psychiatry, 77, 193, 10.1136/jnnp.2005.074203
Meador, 2006, In utero antiepileptic drug exposure fetal death and malformations, Neurology, 67, 407, 10.1212/01.wnl.0000227919.81208.b2
Hill, 2010, Teratogenic effects of antiepileptic drugs, Expert Rev Neurother, 10, 943, 10.1586/ern.10.57
Kulaga, 2011, Antiepileptic drug use during pregnancy: perinatal outcomes, Seizure, 20, 667, 10.1016/j.seizure.2011.06.012
Tomson, 2015, Major congenital malformations in children of women with epilepsy, Seizure, 28, 46, 10.1016/j.seizure.2015.02.019
Tomson, 2005, Teratogenicity of antiepileptic drugs: state of the art, Curr Opin Neurol, 18, 135, 10.1097/01.wco.0000162854.67767.06
Tomson, 2007, Antiepileptic drug exposure and major congenital malformations: the role of pregnancy registries, Epilepsy Behav, 11, 277, 10.1016/j.yebeh.2007.08.015
Tomson, 2009, Teratogenic effects of antiepileptic medications, Neurol Clin, 27, 993, 10.1016/j.ncl.2009.06.006
Yeh, 2017, Antiepileptic drug use among women from the Taiwanese registry of epilepsy and pregnancy: obstetric complications and fetal malformation outcomes, PLoS One, 12, 10.1371/journal.pone.0189497
Laganà, 2016, Management of women with epilepsy: from preconception to post-partum, Arch Gynecol Obstet, 293, 493, 10.1007/s00404-015-3968-7
Viale, 2015, EBM CONNECT collaboration. Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta-analysis, Lancet, 386, 1845, 10.1016/S0140-6736(15)00045-8
Vitale, 2016, Psychopharmacotherapy in pregnancy and breastfeeding, Obstet Gynecol Surv, 71, 721, 10.1097/OGX.0000000000000369
US Food and Drug Administration, 2011
Tomson, 2011, Dose-dependent risk of malformations with antiepileptic drugs: analysis of data from the EURAP epilepsy and pregnancy registry, Lancet Neurol, 10, 609, 10.1016/S1474-4422(11)70107-7
Vajda, 2012, Teratogenicity of the newer antiepileptic drugs–the Australian experience, J Clin Neurosci, 19, 57, 10.1016/j.jocn.2011.08.003
Tomson, 2008, Teratogenic effects of antiepileptic drugs, Seizure, 17, 166, 10.1016/j.seizure.2007.11.016
Hamdi, 2017, In utero exposure to oxcarbazepine causes congenital anomalies in albino rat fetuses, JAMPS, 12, 1, 10.9734/JAMPS/2017/32345
Veiby, 2014, Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy, J Neurol, 261, 579, 10.1007/s00415-013-7239-x
Reimers, 2012, Second-generation antiepileptic drugs and pregnancy: a guide for clinicians, Expert Rev Neurother, 12, 707, 10.1586/ern.12.32
Łuszczki, 2009, Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions, Pharmacol Rep, 61, 197, 10.1016/S1734-1140(09)70024-6
Costa, 2018, Eslicarbazepine acetate exposure in pregnant women with epilepsy, Seizure, 58, 72, 10.1016/j.seizure.2018.04.007
Johannessen, 2010, Drug interactions involving the new second-and third-generation antiepileptic drugs, Expert Rev Neurother, 10, 119, 10.1586/ern.09.136
Arzimanoglou, 2010, The evolution of antiepileptic drug development and regulation, Epileptic Disord, 12, 3, 10.1684/epd.2010.0303
Vohora, 2010, Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third generation antiepileptic drugs, Drugs Today, 46, 265, 10.1358/dot.2010.46.4.1445795
Silverstein, 2012, Recent clinical trials of third-generation antiepileptic drugs, Neurol Rep, 5
Pressman, 2013, Optimal use of the newest antiepileptic drugs and generics, Neurol Rep, 5, 24
WHO, 2019
European Medicines Agency, 2019
US Food and Drug Administration, 2019
Ambrósio, 2001, Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels, Biochem Pharmacol, 61, 1271, 10.1016/S0006-2952(01)00584-6
Lattanzi, 2018, Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy, Core Evid, 13, 21, 10.2147/CE.S142858
Carcak, 2017, Seizures and antiepileptic drugs: from pathophysiology to clinical practice, Curr Pharm Des, 23, 6376, 10.2174/1381612823666171115101557
Toth, 2014, Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain, Ther Adv Drug Saf, 5, 38, 10.1177/2042098613505614
Weissmann, 2013, Acute effects of pregabalin on the function and cellular distribution of Ca V 2.1 in HEK293t cells, Brain Res Bull, 90, 107, 10.1016/j.brainresbull.2012.10.001
Taylor, 2009, Mechanisms of analgesia by gabapentin and pregabalin–calcium channel α2‐δ [Cavα2‐δ] ligands, Pain, 142, 13, 10.1016/j.pain.2008.11.019
Stahl, 2013, The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?, Trends Pharmacol Sci, 34, 332, 10.1016/j.tips.2013.04.001
Veiby, 2015, Epilepsy and recommendations for breastfeeding, Seizure, 28, 57, 10.1016/j.seizure.2015.02.013
Winterfeld, 2016, Pregnancy outcome following maternal exposure to pregabalin may call for concern, Neurology, 86, 2251, 10.1212/WNL.0000000000002767
US Food and Drug Administration, 2019
Morse, 2016, Embryo‐fetal developmental toxicity studies with pregabalin in mice and rabbits, Birth Defects Res B Dev Reprod Toxicol, 107, 85, 10.1002/bdrb.21174
Morse, 2016, Developmental toxicity studies with pregabalin in rats: significance of alterations in skull bone morphology, Birth Defects Res B Dev Reprod Toxicol, 107, 94, 10.1002/bdrb.21175
Etemad, 2013, Teratogenic effects of pregabalin in mice, Iran J Basic Med Sci, 16, 1065
US Food and Drug Administration, 2019
White, 2008, The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models, Epilepsia, 49, 1213, 10.1111/j.1528-1167.2008.01552.x
US Food and Drug Administration, 2019
Mete, 2016, Effects of lacosamide “a novel antiepileptic drug” in the early stages of chicken embryo development, Childs Nerv Syst, 32, 1715, 10.1007/s00381-016-3181-4
Lee, 2013, Teratogenic potential of antiepileptic drugs in the zebrafish model, Biomed Res Int, 2013, 10.1155/2013/726478
European Medicines Agency, 2019
US Food and Drug Administration, 2019
US Food and Drug Administration, 2019
Stephen, 2018, Brivaracetam: a novel antiepileptic drug for focal-onset seizures, Ther Adv Neurol Disord, 11, 1, 10.1177/1756285617742081
US Food and Drug Administration, 2019
European Medicines Agency, 2019
US Food and Drug Administration, 2019
US Food and Drug Administration, 2019
Singh, 2014, Effect of in utero exposure of gabapentin and valproic acid on skeletal anomalies in rat fetuses, Natl Acad Sci Lett, 37, 117, 10.1007/s40009-013-0206-3
Singh, 2018, Teratogenic effects of third-generation antiepileptic drug, pregabalin: an in vivo study, Curr Drug Saf, 13, 113, 10.2174/1574886313666180402145645
Fan, 2016, The impact of anti-epileptic drugs on growth and bone metabolism, Int J Mol Sci, 17, 1242, 10.3390/ijms17081242
Briggs, 2017
Afshar, 2009, Teratogenic effects of gabapentin on the skeletal system of Balb/C mice fetuses, Neurosciences(Riyadh), 14, 239
Vormann, 1986, Effect of valproate on zinc metabolism in fetal and maternal rats fed normal and zinc-deficient diets, Biol Trace Elem Res, 10, 25, 10.1007/BF02795316
Ahmed, 2018, Maternal thyroid dysfunctions and neonatal bone maldevelopment, Am Res J Endocrinol, 2, 1
Ahmed, 2017, Maternal carbamazepine alters fetal neuroendocrine-cytokines axis, Toxicology, 382, 59, 10.1016/j.tox.2017.03.002
Keen, 1989, The effect of valproic acid on 65Zn distribution in the pregnant rat, J Nutr, 119, 607, 10.1093/jn/119.4.607
Akbari, 2004, Altered plasma zinc level contributes to the developmental toxicity of valproic acid in skeletal system of rat, Acta Med Iran, 42, 10
Ahmed, 2017, Antiepileptic drugs and developmental neuroendocrine dysfunction: every why has a wherefore, Arch Med (Oviedo), 9, 2
Bank, 2017, Placental passage of antiepileptic drugs at delivery and neonatal outcomes, Epilepsia, 58, e82, 10.1111/epi.13733
Shim, 2010, Embryonic expression of cyclooxygenase-2 causes malformations in axial skeleton, J Biol Chem, 285, 16206, 10.1074/jbc.M109.078576
Fadel, 2012, Effect of prenatal administration of therapeutic doses of topiramate on ossification of ribs and vertebrae in rat fetuses, Rom J Morphol Embryol, 53, 321
Rauch, 2001, The developing bone: slave or master of its cells and molecules?, Pediatr Res, 50, 309, 10.1203/00006450-200109000-00003
Petersen, 2017, Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies, Clin Epidemiol, 9, 95, 10.2147/CLEP.S118336
Golembesky, 2017, Outcomes following exposure to the antiepileptic drug lacosamide during pregnancy–results from a global safety database (P5.231), Neurology, 88
Vazquez, 2015, Review of pregnancies events in perampanel clinical studies
US Food and Drug Administration, 2019
Patsalos, 2015, The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist, Epilepsia, 56, 12, 10.1111/epi.12865
Bialer, 2017, Progress report on new antiepileptic drugs: a summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII), Epilepsia, 58, 181, 10.1111/epi.13634
US Food and Drug Administration, 2019